#METABOLOMICS WORKBENCH hormel101_20161202_130330_mwtab.txt DATATRACK_ID:785 STUDY_ID:ST000514 ANALYSIS_ID:AN000787 PROJECT_ID:PR000383
VERSION             	1
CREATED_ON             	December 8, 2016, 3:23 pm
#PROJECT
PR:PROJECT_TITLE                 	Mayo Metabolomics Pilot and Feasibility Award: Role of muscle insulin and IGF-1
PR:PROJECT_TITLE                 	signaling on serum and muscle metabolite profiles
PR:PROJECT_SUMMARY               	Skeletal muscle insulin resistance is a cardinal feature of the pathogenesis of
PR:PROJECT_SUMMARY               	type 2 diabetes. Insulin and IGF-1 signal through their highly related receptors
PR:PROJECT_SUMMARY               	to impact on many aspects of muscle physiology including glucose homeostasis,
PR:PROJECT_SUMMARY               	protein metabolism, and mitochondrial function. Early physiological studies, as
PR:PROJECT_SUMMARY               	well as recent large scale metabolomic studies, have shown that changes in
PR:PROJECT_SUMMARY               	specific pools of circulating amino acid metabolites, such as branched chain
PR:PROJECT_SUMMARY               	amino acids (BCAAs), are associated with insulin resistance and can predict
PR:PROJECT_SUMMARY               	future diabetes, but the source and impact of these changes in amino acids are
PR:PROJECT_SUMMARY               	not fully understood. We have recently generated mice which lack insulin
PR:PROJECT_SUMMARY               	receptors (IR) or IGF-1 receptors (IGF1R) or both in muscle using Cre lox
PR:PROJECT_SUMMARY               	recombination. We find that mice which lack only IR or only IGF1R in muscle show
PR:PROJECT_SUMMARY               	minimal changes in muscle mass, but do display increases in proteasomal activity
PR:PROJECT_SUMMARY               	and autophagy in muscle. On the other hand, mice with combined loss of both IR
PR:PROJECT_SUMMARY               	and IGF1R display markedly decreased muscle mass and enhanced degradation
PR:PROJECT_SUMMARY               	pathways, associated with increased protein synthesis, and display changes in
PR:PROJECT_SUMMARY               	mitochondrial gene regulation, indicating that both receptors can compensate to
PR:PROJECT_SUMMARY               	some extent for loss of the other. We hypothesize that IR and IGF1R signaling in
PR:PROJECT_SUMMARY               	muscle coordinate amino acid metabolite turnover and fuel
PR:PROJECT_SUMMARY               	substrate/mitochondrial metabolism, and that in insulin resistant states,
PR:PROJECT_SUMMARY               	changes in protein metabolism and mitochondrial function disrupt relative
PR:PROJECT_SUMMARY               	proportions of amino acid metabolites, which in turn contribute to diabetes risk
PR:PROJECT_SUMMARY               	and/or muscle pathology. We propose to test this hypothesis by performing large
PR:PROJECT_SUMMARY               	scale metabolomics on serum and muscle from mice lacking IR, IGF1R or both in
PR:PROJECT_SUMMARY               	muscle, and we will compare these changes to both insulin deficient
PR:PROJECT_SUMMARY               	streptozotocin-treated and insulin resistant diet-induced obese mouse models. To
PR:PROJECT_SUMMARY               	gain insight into which pathways are critical for metabolite changes, we will
PR:PROJECT_SUMMARY               	also treat mice with specific inhibitors of mTOR, a common protein synthesis
PR:PROJECT_SUMMARY               	pathway, as well as inhibitors of autophagy or proteasomal degradation and
PR:PROJECT_SUMMARY               	determine metabolite concentrations in muscle and serum. These studies will
PR:PROJECT_SUMMARY               	identify specific pathways that impact amino acid and mitochondrial metabolite
PR:PROJECT_SUMMARY               	flux which are perturbed in insulin resistant states, and potentially provide
PR:PROJECT_SUMMARY               	insights into how changes in amino acid metabolites contribute to diabetes risk.
PR:INSTITUTE                     	Mayo Clinic
PR:LAST_NAME                     	O'Neill
PR:FIRST_NAME                    	Brian
PR:ADDRESS                       	One Joslin Place, Boston, MA 02215
PR:EMAIL                         	brian.o'neill@joslin.harvard.edu
PR:PHONE                         	617-309-2400
#STUDY
ST:STUDY_TITLE                   	Inhibition of autophagy/proteasome degradation or inhibition of protein
ST:STUDY_TITLE                   	synthesis in models of muscle insulin resistance affect amino acids metabolites
ST:STUDY_TITLE                   	in serum
ST:STUDY_SUMMARY                 	To determine which protein degradation pathways downstream of IR and IGF1R
ST:STUDY_SUMMARY                 	contribute to changes in amino acid and mitochondrial metabolite pools, we will
ST:STUDY_SUMMARY                 	treat control, M-IR-/-, MIGIRKO, and HFD obese mice with inhibitors of autophagy
ST:STUDY_SUMMARY                 	or proteasome. We will treat 5 animals each of control, M-IR-/-, MIGIRKO, and
ST:STUDY_SUMMARY                 	HFD mice with vehicle, colchicine to inhibit autophagy, or MG132 to inhibit
ST:STUDY_SUMMARY                 	proteasome activity, then measure amino acid metabolites in serum.
ST:INSTITUTE                     	Mayo Clinic
ST:LAST_NAME                     	O'Neill
ST:FIRST_NAME                    	Brian
ST:ADDRESS                       	One Joslin Place, Boston, MA 02215
ST:EMAIL                         	brian.o'neill@joslin.harvard.edu
ST:PHONE                         	617-309-2400
#SUBJECT
SU:SUBJECT_TYPE                  	Mouse
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	613	ms5629-1	Group:control | Genotype:Irlox IGFRlox | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	595	ms5629-2	Group:control | Genotype:Irlox IGFRlox | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1837	ms5629-3	Group:control | Genotype:Irlox IGFRlox | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	2005	ms5629-4	Group:control | Genotype:Irlox | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1942	ms5629-5	Group:control | Genotype:Irlox | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1956	ms5629-6	Group:control | Genotype:Irlox | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1989	ms5629-7	Group:control | Genotype:IR -/- IGFR -/- | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	615	ms5629-8	Group:MIGIRKO | Genotype:IR -/- IGFR -/- | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	597	ms5629-9	Group:MIGIRKO | Genotype:IR -/- IGFR -/- | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1838	ms5629-10	Group:MIGIRKO | Genotype:IR -/- IGFR -/- | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1815	ms5629-11	Group:MIGIRKO | Genotype:IR -/- IGFR -/- | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	2028	ms5629-12	Group:MIGIRKO | Genotype:IR -/- IGFR -/- | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	2029	ms5629-13	Group:MIGIRKO | Genotype:IR -/- IGFR -/- | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1947	ms5629-14	Group:HFD | Genotype:Irlox | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1950	ms5629-15	Group:HFD | Genotype:Irlox | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1960	ms5629-16	Group:HFD | Genotype:Irlox | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1964	ms5629-17	Group:HFD | Genotype:Irlox IGFRlox | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1988	ms5629-18	Group:HFD | Genotype:Irlox | Treatment:saline	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1849	ms5629-19	Group:Control colch | Genotype:Irlox IGFRlox | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	606	ms5629-20	Group:Control colch | Genotype:Irlox IGFRlox | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1826	ms5629-21	Group:Control colch | Genotype:Irlox IGFRlox | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1847	ms5629-22	Group:Control colch | Genotype:Irlox IGFRlox | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1818	ms5629-23	Group:Control colch | Genotype:- | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1944	ms5629-24	Group:Control colch | Genotype:Irlox | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1958	ms5629-25	Group:Control colch | Genotype:Irlox | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1852	ms5629-26	Group:MIGIRKO colch | Genotype:IR -/- IGFR -/- | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1853	ms5629-27	Group:MIGIRKO colch | Genotype:IR -/- IGFR -/- | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1856	ms5629-28	Group:MIGIRKO colch | Genotype:IR -/- IGFR -/- | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1817	ms5629-29	Group:MIGIRKO colch | Genotype:IR -/- IGFR -/- | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	607	ms5629-30	Group:MIGIRKO colch | Genotype:IR -/- IGFR -/- | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1824	ms5629-31	Group:MIGIRKO colch | Genotype:IR -/- IGFR -/- | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1951	ms5629-32	Group:HFD + Colch | Genotype:Irlox | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1952	ms5629-33	Group:HFD + Colch | Genotype:Irlox | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1965	ms5629-34	Group:HFD + Colch | Genotype:Irlox IGFRlox | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1991	ms5629-35	Group:HFD + Colch | Genotype:Irlox | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
SUBJECT_SAMPLE_FACTORS           	1994	ms5629-36	Group:HFD + Colch | Genotype:Irlox | Treatment:Colch	assay=Concentration of AA  + metabolites in serum
#COLLECTION
CO:COLLECTION_SUMMARY            	mouse serum
#TREATMENT
TR:TREATMENT_SUMMARY             	To determine which protein degradation pathways downstream of IR and IGF1R
TR:TREATMENT_SUMMARY             	contribute to changes in amino acid and mitochondrial metabolite pools, we will
TR:TREATMENT_SUMMARY             	treat control, M-IR-/-, MIGIRKO, and HFD obese mice with inhibitors of autophagy
TR:TREATMENT_SUMMARY             	or proteasome. We will treat 5 animals each of control, M-IR-/-, MIGIRKO, and
TR:TREATMENT_SUMMARY             	HFD mice with vehicle, colchicine to inhibit autophagy, or MG132 to inhibit
TR:TREATMENT_SUMMARY             	proteasome activity, then measure amino acid metabolites in serum as well as TCA
TR:TREATMENT_SUMMARY             	cycle and amino acid metabolites in muscle tissue.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Concentration of amino acid metabolites in serum
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Waters Acquity
CH:COLUMN_NAME                   	Waters Acquity BEH C18 (150 x 2.1mm, 1.7um)
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:MS_COMMENTS                   	-
MS:INSTRUMENT_NAME               	Thermo Quantum Ultra
MS:INSTRUMENT_TYPE               	Triple quadrupole
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS         	uM
MS_METABOLITE_DATA_START
Samples	ms5629-1	ms5629-2	ms5629-3	ms5629-4	ms5629-5	ms5629-6	ms5629-7	ms5629-8	ms5629-9	ms5629-10	ms5629-11	ms5629-12	ms5629-13	ms5629-14	ms5629-15	ms5629-16	ms5629-17	ms5629-18	ms5629-19	ms5629-20	ms5629-21	ms5629-22	ms5629-23	ms5629-24	ms5629-25	ms5629-26	ms5629-27	ms5629-28	ms5629-29	ms5629-30	ms5629-31	ms5629-32	ms5629-33	ms5629-34	ms5629-35	ms5629-36
Factors	Group:control | Genotype:Irlox IGFRlox | Treatment:saline	Group:control | Genotype:Irlox IGFRlox | Treatment:saline	Group:control | Genotype:Irlox IGFRlox | Treatment:saline	Group:control | Genotype:Irlox | Treatment:saline	Group:control | Genotype:Irlox | Treatment:saline	Group:control | Genotype:Irlox | Treatment:saline	Group:control | Genotype:IR -/- IGFR -/- | Treatment:saline	Group:MIGIRKO | Genotype:IR -/- IGFR -/- | Treatment:saline	Group:MIGIRKO | Genotype:IR -/- IGFR -/- | Treatment:saline	Group:MIGIRKO | Genotype:IR -/- IGFR -/- | Treatment:saline	Group:MIGIRKO | Genotype:IR -/- IGFR -/- | Treatment:saline	Group:MIGIRKO | Genotype:IR -/- IGFR -/- | Treatment:saline	Group:MIGIRKO | Genotype:IR -/- IGFR -/- | Treatment:saline	Group:HFD | Genotype:Irlox | Treatment:saline	Group:HFD | Genotype:Irlox | Treatment:saline	Group:HFD | Genotype:Irlox | Treatment:saline	Group:HFD | Genotype:Irlox IGFRlox | Treatment:saline	Group:HFD | Genotype:Irlox | Treatment:saline	Group:Control colch | Genotype:Irlox IGFRlox | Treatment:Colch	Group:Control colch | Genotype:Irlox IGFRlox | Treatment:Colch	Group:Control colch | Genotype:Irlox IGFRlox | Treatment:Colch	Group:Control colch | Genotype:Irlox IGFRlox | Treatment:Colch	Group:Control colch | Genotype:- | Treatment:Colch	Group:Control colch | Genotype:Irlox | Treatment:Colch	Group:Control colch | Genotype:Irlox | Treatment:Colch	Group:MIGIRKO colch | Genotype:IR -/- IGFR -/- | Treatment:Colch	Group:MIGIRKO colch | Genotype:IR -/- IGFR -/- | Treatment:Colch	Group:MIGIRKO colch | Genotype:IR -/- IGFR -/- | Treatment:Colch	Group:MIGIRKO colch | Genotype:IR -/- IGFR -/- | Treatment:Colch	Group:MIGIRKO colch | Genotype:IR -/- IGFR -/- | Treatment:Colch	Group:MIGIRKO colch | Genotype:IR -/- IGFR -/- | Treatment:Colch	Group:HFD + Colch | Genotype:Irlox | Treatment:Colch	Group:HFD + Colch | Genotype:Irlox | Treatment:Colch	Group:HFD + Colch | Genotype:Irlox IGFRlox | Treatment:Colch	Group:HFD + Colch | Genotype:Irlox | Treatment:Colch	Group:HFD + Colch | Genotype:Irlox | Treatment:Colch
Histidine	36.8	35.4	36.0	52.4	40.2	47.9	33.0	37.5	28.5	32.0	25.7	34.8	42.1	39.6	26.4	35.9	26.3	35.7	30.8	24.1	32.5	24.7	32.1	27.7	20.7	26.9	25.9	27.8	29.9	21.4	19.5	18.2	16.0	22.1	21.3	21.7
Hydroxyproline	14.7	17.0	18.6	19.0	20.0	14.8	12.2	14.9	14.9	19.5	16.1	16.8	22.3	19.3	12.8	15.4	13.5	11.4	20.7	15.9	24.3	13.7	21.5	20.0	18.0	14.3	14.4	18.6	19.7	15.9	17.2	8.3	7.8	9.3	9.4	9.6
1-Methylhistidine	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
3-Methylhistidine	1.5	7.2	6.9	7.3	7.2	7.5	2.6	6.6	4.6	5.7	1.7	1.3	3.4	1.6	4.6	5.5	3.7	5.1	3.4	3.0	7.9	3.7	5.1	10.7	6.7	6.0	3.4	5.9	3.5	3.6	4.4	2.3	4.4	7.3	2.9	4.5
Phosphoethanolamine	4.9	4.5	6.8	5.1	6.2	8.2	7.3	7.4	6.6	7.9	6.4	6.9	7.4	12.3	5.9	8.7	6.0	6.5	7.3	5.8	7.5	6.2	9.5	4.0	6.3	7.0	7.2	8.7	5.5	4.5	7.5	9.9	4.8	6.7	7.1	7.1
Carnosine	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Anserine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Ethanolamine	8.6	10.9	15.4	17.9	16.2	22.1	19.7	10.9	8.6	12.5	9.8	10.6	13.5	20.0	19.2	24.4	20.1	15.7	16.9	10.2	19.3	15.0	12.9	15.7	14.5	13.1	12.4	12.2	9.3	8.8	12.4	17.0	13.3	16.2	16.6	14.1
Aspartic Acid	7.7	6.8	12.5	6.6	10.6	9.9	11.6	8.1	7.6	10.4	8.8	10.2	13.5	13.3	10.3	13.7	9.3	10.3	14.0	8.7	23.0	10.1	13.7	6.9	8.7	11.4	8.9	9.3	7.4	6.8	12.8	9.0	5.7	7.4	10.3	9.3
Sarcosine	0.8	1.9	1.0	0.6	1.5	0.4	0.8	0.5	0.5	0.8	0.5	0.6	1.1	0.0	0.0	0.0	0.3	0.5	1.1	1.1	1.7	0.9	0.5	2.3	1.6	0.8	0.6	1.0	0.9	0.8	0.8	0.0	0.0	0.2	0.0	0.2
beta-alanine	1.0	2.5	1.4	0.8	2.1	0.5	1.0	0.6	0.6	1.1	0.5	0.7	1.5	-0.1	-0.2	-0.2	0.5	0.9	1.4	1.4	2.6	1.1	0.6	3.1	2.1	1.0	0.8	1.4	1.0	1.0	1.0	-0.1	-0.1	0.3	0.0	0.2
gamma-Amino-N-butyric-acid	0.1	0.1	0.2	0.2	0.3	0.9	1.2	0.2	0.1	0.2	0.1	0.1	0.1	0.2	0.3	0.2	0.2	0.3	0.2	0.1	0.4	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.1	0.2	0.2	0.2	0.1	0.5	0.1
alpha-Aminoadipic-acid	12.4	5.6	9.0	6.2	6.8	3.3	3.7	14.1	7.2	8.3	8.2	5.8	6.0	10.9	15.2	15.3	10.5	11.0	6.4	7.8	9.2	7.0	12.1	10.7	7.5	6.5	7.4	7.2	11.5	6.6	9.1	11.5	11.2	10.4	9.6	14.2
beta-Aminoisobutyric-acid	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Hydroxylysine 1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Hydroxylysine 2	0.9	1.2	0.8	0.5	0.8	0.5	0.2	0.5	0.4	0.3	0.4	0.3	0.6	0.0	0.0	0.0	0.1	0.0	0.4	0.2	0.5	0.3	0.6	0.4	0.4	0.4	0.2	0.0	0.4	0.3	0.2	0.0	0.0	0.0	0.0	0.0
alpha-Amino-N-butyric-acid	5.2	2.8	3.1	3.9	4.2	3.3	3.6	3.0	2.2	3.5	1.8	4.1	4.2	38.7	52.4	58.3	3.1	6.6	3.4	5.0	1.7	2.5	2.2	7.1	3.0	3.6	3.9	3.8	2.7	2.2	1.6	10.1	8.7	4.6	9.4	8.3
Cystathionine 1	2.2	3.0	2.2	1.6	2.8	1.5	0.7	0.9	0.3	2.0	0.6	2.1	1.7	2.1	1.4	3.2	1.1	3.2	1.9	6.4	2.6	1.7	1.7	5.3	3.9	0.9	1.7	0.9	1.1	2.1	1.3	1.1	0.5	3.2	2.3	2.2
Cystathionine 2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Methionine	78.4	129.2	55.2	64.7	96.4	61.2	34.6	60.4	62.6	55.4	64.8	52.3	74.7	59.6	57.2	82.2	62.9	65.7	72.1	63.6	107.4	58.0	77.1	97.0	84.8	51.9	42.4	46.5	70.9	62.4	69.5	40.4	41.8	48.5	51.4	50.6
allo-Isoleucine	0.0	0.6	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.4	0.0	0.2	0.0	0.0	0.0
Homocystine	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Asparagine	45.0	77.7	43.0	68.7	66.4	76.4	60.6	60.2	54.0	53.6	44.4	50.3	83.0	65.7	68.3	104.0	73.2	101.1	55.3	51.3	78.7	37.3	51.1	88.1	63.3	42.3	39.2	60.0	59.7	68.5	38.7	42.9	59.2	47.7	79.2	91.6
Arginine	80.8	107.4	97.5	74.4	89.1	62.0	48.7	61.1	51.4	65.0	79.9	53.1	95.1	74.5	30.5	61.9	54.3	97.7	94.4	70.6	157.3	75.4	89.4	98.6	82.0	93.9	67.4	54.0	92.5	70.3	60.6	58.3	41.2	55.1	54.6	65.2
Taurine	446.4	587.1	723.3	608.3	573.3	530.1	518.1	521.4	388.9	574.6	431.1	438.2	626.7	895.4	854.9	1187.3	703.2	991.5	745.3	572.5	1027.8	577.4	636.3	661.4	564.5	577.6	604.2	662.4	510.4	383.5	555.2	627.8	545.9	673.1	750.7	832.9
Serine	121.4	180.4	143.6	156.5	173.0	151.6	135.0	167.6	145.6	143.7	134.0	161.7	224.1	152.9	156.4	225.8	188.1	252.5	138.5	130.1	190.4	108.4	152.9	172.8	137.9	140.2	133.1	166.6	171.5	171.2	123.7	105.2	115.1	143.3	209.4	200.2
Glutamine	456.5	438.1	660.2	624.8	573.6	581.7	688.0	432.8	446.2	620.3	586.7	557.4	787.5	703.0	738.0	1082.6	725.3	748.7	632.8	504.3	616.3	534.7	634.7	729.1	654.6	651.2	609.6	617.5	624.8	454.8	359.0	619.8	618.1	556.1	751.3	878.9
Glycine	221.7	379.5	281.5	329.8	336.3	290.8	263.0	323.3	267.1	290.1	235.3	248.0	372.3	146.8	135.4	148.9	291.3	307.6	249.5	214.8	312.7	214.8	226.4	320.7	255.2	247.0	274.3	373.7	254.6	247.0	224.5	128.1	142.5	230.3	223.3	244.4
Citrulline	40.6	69.8	66.3	67.4	67.7	61.0	60.7	29.4	36.0	49.7	34.4	30.9	59.1	61.1	55.9	94.5	61.7	72.9	68.0	62.8	99.5	56.5	53.8	98.4	77.6	60.7	45.5	49.1	46.0	33.9	43.3	40.0	45.1	44.8	66.7	55.4
Glutamic Acid	32.1	34.5	78.3	30.8	39.8	47.7	53.8	40.0	33.2	49.9	33.9	35.6	55.2	64.6	48.4	71.7	33.3	46.1	53.7	37.9	100.1	47.7	59.0	28.0	40.2	51.7	45.6	55.5	41.7	29.4	56.0	41.5	24.0	39.5	37.5	34.8
Threonine	147.7	228.8	137.5	128.9	159.8	93.0	81.6	155.9	141.3	139.2	130.1	135.2	202.0	193.0	195.3	252.6	200.8	188.8	134.0	151.7	197.4	116.4	162.4	176.2	129.5	121.2	113.8	120.7	184.2	166.6	118.2	112.6	117.3	166.4	187.4	194.7
Alanine	384.0	678.0	461.9	755.8	621.1	585.7	435.1	417.1	415.4	464.1	346.9	452.8	937.1	642.7	655.5	905.4	754.3	1009.9	470.9	441.0	802.3	382.9	475.9	954.1	603.0	423.5	330.4	545.2	460.4	404.3	391.1	358.8	434.6	397.0	776.8	683.9
Proline	104.4	154.7	91.4	111.9	128.0	129.1	76.4	88.8	83.9	79.7	77.0	61.0	138.9	98.9	80.9	147.7	111.0	127.6	102.7	84.9	167.3	74.8	101.7	173.4	116.8	75.9	61.9	80.5	96.0	83.2	72.8	51.6	60.7	62.5	99.5	92.0
Ornithine	49.6	63.1	45.3	42.1	39.8	38.1	36.7	42.7	43.8	40.1	43.9	41.1	70.0	51.0	73.0	94.9	44.4	44.3	44.7	32.4	49.2	28.9	46.5	39.4	26.7	38.7	33.4	42.8	47.2	39.9	34.4	19.4	21.4	22.8	32.4	31.6
Lysine	343.7	384.7	274.4	275.2	272.3	198.1	158.8	317.5	298.0	337.8	337.9	306.1	451.3	394.3	298.0	466.7	399.5	422.3	291.3	291.5	371.5	255.3	322.4	382.7	253.5	272.3	269.4	256.5	409.8	318.5	258.2	234.9	194.3	272.6	293.3	276.7
Cystine	13.7	8.5	6.7	11.0	11.1	7.8	2.0	14.8	7.7	5.9	15.9	5.4	4.5	3.7	9.1	9.5	16.0	16.4	10.9	9.5	14.9	4.2	19.0	39.7	4.7	7.8	6.9	7.2	21.2	16.3	3.9	7.7	9.7	7.1	14.8	15.4
Tyrosine	88.9	150.5	85.1	85.9	101.4	119.4	80.2	96.9	83.2	81.3	77.7	53.7	71.5	69.8	72.1	84.1	61.5	88.5	63.6	68.9	121.1	62.9	68.3	103.0	74.5	58.2	48.0	59.5	78.3	78.1	67.7	43.2	43.5	40.3	57.2	60.7
Valine	192.5	226.3	153.6	164.0	223.6	163.1	136.2	158.8	147.6	177.1	164.1	177.5	229.5	198.5	207.5	261.6	221.7	273.5	184.0	188.1	259.5	163.3	172.2	225.2	156.4	169.1	168.2	219.5	203.5	193.4	138.9	140.0	148.3	158.5	219.2	245.9
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name
Histidine
Hydroxyproline
1-Methylhistidine
3-Methylhistidine
Phosphoethanolamine
Carnosine
Anserine
Ethanolamine
Aspartic Acid
Sarcosine
beta-alanine
gamma-Amino-N-butyric-acid
alpha-Aminoadipic-acid
beta-Aminoisobutyric-acid
Hydroxylysine 1
Hydroxylysine 2
alpha-Amino-N-butyric-acid
Cystathionine 1
Cystathionine 2
Methionine
allo-Isoleucine
Homocystine
Asparagine
Arginine
Taurine
Serine
Glutamine
Glycine
Citrulline
Glutamic Acid
Threonine
Alanine
Proline
Ornithine
Lysine
Cystine
Tyrosine
Valine
METABOLITES_END
#END